Verrica Pharmaceuticals Doses First U.S. Patient in Second Pivotal Common Warts Trial

Product / Tech
โดย GlobeNewswire·Read original
Summary · why it matters

Verrica Pharmaceuticals announced that the first U.S. patient has been dosed in COVE-3, the second pivotal clinical trial of its global Phase 3 program evaluating YCANTH for the treatment of common warts. The company's Japanese development partner, Torii Pharmaceutical, also recently dosed the first Japanese patient in the same study. The Phase 3 program consists of two double-blind, randomized, vehicle-controlled trials, with COVE-2 enrolling only in the U.S. and COVE-3 enrolling in both the U.S. and Japan. Verrica noted that COVE-2 has already surpassed 50% of its targeted U.S. enrollment, and a long-term follow-up study, COVE-4, is also underway. If approved, YCANTH would be the first FDA-approved therapy for common warts, a condition affecting an estimated 22 million people in the U.S. alone.

Impact on stocks 2

Health Care▲ · 1 stocks
Verrica Pharmaceuticals Inc
VRCA
▲ PositiveTechnologyrelevance

First patient dosed in second pivotal trial for YCANTH, a potential first FDA-approved therapy for common warts.

Biotech & Genomic Medicine▲ · 1 stocks
Shionogi & Co., Ltd.
4507
± MixedTechnologyrelevance

Torii Pharmaceutical is the Japanese development partner, but the article only mentions they dosed the first Japanese patient; no direct impact on Shionogi.

Off-coverage companies 1

Torii Pharmaceutical Co., Ltd.Private▲ Positive
Technologyrelevance

Japanese development partner dosed first patient in same study, advancing the program.

© 2026 MarketDXNews